December 2, 2023

Sam­sung Bioepis reached a deal this week that would al­low its Ste­lara biosim­i­lar hope­ful to launch in Feb­ru­ary 2025, adding to mount­ing com­pe­ti­tion against John­son

The FDA and Apel­lis Phar­ma­ceu­ti­cals have up­dat­ed the la­bel for Syfovre — an in­jec­tion for late-stage wet age-re­lat­ed mac­u­lar de­gen­er­a­tion — to ad­dress the po­ten­tial

What do pop­u­lar Stan­ley in­su­lat­ed cups have in com­mon with two phar­ma mi­graine brands? They’re all trans­for­ma­tion­al dig­i­tal brands, ac­cord­ing to new re­search out this

The Eu­ro­pean Med­i­cines Agency’s safe­ty com­mit­tee on Fri­day raised more ques­tions for the mak­ers of GLP-1 weight loss drugs af­ter re­port­ed cas­es of thoughts of

No­var­tis’ lat­est cam­paign for its mul­ti­ple scle­ro­sis drug Kes­imp­ta stars for­mer “So­pra­nos” ac­tor Jamie-Lynn Sigler, who has re­laps­ing MS. Sigler was di­ag­nosed with MS at

Ot­su­ka Phar­ma­ceu­ti­cal is boost­ing a long-run­ning men­tal health pro­gram with a dig­i­tal re­launch, open­ing broad­er avail­abil­i­ty for the free re­source. Called WILD 5, now spon­sored

Cy­tonus Ther­a­peu­tics, a small biotech com­pa­ny north of San Diego, raised $11.7 mil­lion in Se­ries A fi­nanc­ing to en­gi­neer cells as de­liv­ery ves­sels for ge­net­ic

Tharim­mune clos­es $11M in pub­lic of­fer­ing: The com­pa­ny, which is de­vel­op­ing ther­a­pies that aim to treat rare, in­flam­ma­to­ry, and on­co­log­ic con­di­tions, an­nounced Thurs­day that it